**Author details**

Sarwat Fatima1,2\*, Nikki Pui-Yue Lee<sup>3</sup> , Hiu Yee Kwan1,2 and Zhao Xiang Bian1,2

\*Address all correspondence to: sarwat@hkbu.edu.hk

1 Lab of Brain and Gut Research, Centre of Clinical Research for Chinese Medicine, School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR, China

[10] Li XM, Tang ZY, Zhou G, Lui YK, Ye SL. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. Journal of

Emerging Targeted Therapies for Treatment of Hepatocellular Carcinoma (HCC)

http://dx.doi.org/10.5772/intechopen.71480

185

[11] Zhou J, Tang ZY, Fan J, Wu ZQ, Li XM, Liu YK, et al. Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. Journal of Cancer Research and Clinical

[12] Guo JH, Zhu X, Li XT, Yang RJ. Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Chinese Journal of Cancer Research = Chung-kuo yen cheng yen chiu.

[13] Wei T, Zhang LN, Lv Y, Ma XY, Zhi L, Liu C, et al. Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma. Oncotarget. 2014;**5**:10307-10317. DOI: 10.18632/oncotarget.2537

[14] Zheng N, Wei W, Wang Z. Emerging roles of FGF signaling in hepatocellular carcinoma.

[15] Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. The Lancet Oncology. 2009;**10**:25-34.

[16] Li J, Hou Y, Cai XB, Liu B. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. World Journal of Gastroenterology. 2016;**22**:4034-4040.

[17] Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Oncology. 2015;**16**:1344-1354.

[18] Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE

[19] Sun W, Sohal D, Haller DG, Mykulowycz K, Rosen M, Soulen MC, et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular

[20] Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. British Journal of Cancer. 2010;**102**(6):981. DOI: 10.1038/sj.bjc.6605580 [21] Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer

trial. Journal of Hepatology. 2016;**64**:1090-1098. DOI: 10.1016/j.jhep.2016.01.012

carcinoma. Cancer. 2011;**117**:3187-3192. DOI: 10.1002/cncr.25889

Research. 2013;**19**:6614-6623. DOI: 10.1158/1078-0432.ccr-13-1442

Experimental & Clinical Cancer Research: CR. 1998;**17**:13-17

2012;**24**:36-43. DOI: 10.1007/s11670-012-0036-8

Translational Cancer Research. 2016;**5**:1-6

DOI: 10.1016/s1470-2045(08)70285-7

DOI: 10.1016/s1470-2045(15)00198-9

DOI: 10.3748/wjg.v22.i15.4034

Oncology. 2000;**126**:57-61

2 Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR, China

3 Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
